Male osteoporosis

Reumatismo

Volumn 66, Issue 2, 2014, Pages 136-143

  Giusti, A ^a   Bianchi, Gerolamo ^b  

^a GALLIERA HOSPITAL   (Italy)

^b Ospedale La Colletta   (Italy)

Author keywords

Fractures; Male osteoporosis; Treatment

Indexed keywords

ALENDRONIC ACID; ANTICONVULSIVE AGENT; ANTINEOPLASTIC AGENT; BISPHOSPHONIC ACID DERIVATIVE; DENOSUMAB; ESTROGEN; IBANDRONIC ACID; PAMIDRONIC ACID; PARATHYROID HORMONE[1-34]; PLACEBO; RISEDRONIC ACID; SEX HORMONE BINDING GLOBULIN; STRONTIUM RANELATE; THYROID HORMONE; VITAMIN D; ZOLEDRONIC ACID;

AGE DISTRIBUTION; AGING; ANDROGEN DEPRIVATION THERAPY; BONE DENSITY; BONE FRAGILITY; BONE TURNOVER; CORTICOSTEROID INDUCED OSTEOPOROSIS; DUAL ENERGY X RAY ABSORPTIOMETRY; FRAGILITY FRACTURE; HIP FRACTURE; HUMAN; IDIOPATHIC OSTEOPOROSIS; INCIDENCE; LABORATORY TEST; MALE; MALE OSTEOPOROSIS; OSTEOPENIA; OSTEOPOROSIS; PATHOGENESIS; PREVALENCE; PRIMARY OSTEOPOROSIS; PROSTATE CANCER; REVIEW; SECONDARY OSTEOPOROSIS; SENILE OSTEOPOROSIS; SPINE FRACTURE; SPINE RADIOGRAPHY; AGED; COMPLICATION; FEMALE; OSTEOPOROTIC FRACTURES; SEX DIFFERENCE; VERY ELDERLY;

AGED; AGED, 80 AND OVER; FEMALE; HUMANS; MALE; OSTEOPOROSIS; OSTEOPOROTIC FRACTURES; SEX FACTORS;

EID: 84905190397     PISSN: 00487449     EISSN: 22402683     Source Type: Journal    
DOI: 10.4081/reumatismo.2014.786     Document Type: Review

References (28)

1. NIH Consensus development panel on osteoporosis prevention, diagnosis, and therapy. Osteoporosis prevention, diagnosis, and therapy. JAMA. 2001; 285: 785-795.
2. Khosla S, Amin S, Orwoll E. Osteoporosis in men. Endocr Rev. 2008; 29: 441-64.
3. Drake MT, Khosla S. Male osteoporosis. Endocrinol Metab Clin North Am. 2012; 41: 629-41.
4. Looker AC, Orwoll ES, Johnston CC Jr, Lindsay RL, Wahner HW, Dunn WL, et al. Prevalence of low femoral bone density in older U.S. adults from NHANES III. J Bone Miner Res. 1997; 12: 1761-8.
5. Nieves JW, Bilezikian JP, Lane JM, Einhorn TA, Wang Y, Steinbuch M, et al. Fragility fractures of the hip and femur: incidence and patient characteristics. Osteoporos Int. 2010; 21: 399-408.
6. European Prospective Osteoporosis Study (EPOS) Group. Incidence of vertebral fracture in Europe: results from the European Prospective Osteoporosis Study (EPOS). J Bone Miner Res. 2002; 17: 716-24.
7. Cooper C, Cole ZA, Holroyd CR, Earl SC, Harvey NC, Dennison EM, et al. Secular trends in the incidence of hip and other osteoporotic fractures. Osteoporos Int. 2011; 22: 1277-88.
8. Leslie WD, O'Donnell S, Jean S, Lagacé C, Walsh P, Bancej C, et al. Trends in hip fracture rates in Canada. JAMA. 2009; 302: 883-9.
9. Orwoll ES. Osteoporosis in men. In: C. Rosen, ed. Primer on the metabolic bone diseases and disorders of mineral metabolism. 8th ed. Washington, DC: American Society for Bone and Mineral Research; 2013; Chapter 62: 508-13.
10. O'Neill TW, Felsenberg D, Varlow J, Cooper C, Kanis JA, Silman AJ. The prevalence of vertebral deformity in European men and women: the European Vertebral Osteoporosis Study. J Bone Miner Res. 1996; 11: 1010-8.
11. Seeman E. Osteoporosis in men. Osteoporos Int. 1999; 9: S97-110.
12. Riggs BL, Khosla S, Melton LJ 3rd. A unitary model for involutional osteoporosis: estrogen deficiency causes both type I and type II osteoporosis in postmenopausal women and contributes to bone loss in aging men. J Bone Miner Res. 1998; 13: 763-73.
13. Bianchi G, Giusti A, Palummeri E, Girasole G. Hot topics from the 4th International Conference on Osteoporosis in Men. Int J Clin Rheumatol. 2009; 4: 41-4.
14. Giusti A, Penco G, Pioli G. Vitamin D deficiency in HIV-infected patients: a systematic review. Nutr Diet Suppl. 2011; 3: 101-11.
15. Forni GL, Perrotta S, Giusti A, Quarta G, Pitrolo L, Cappellini MD, et al. Neridronate improves bone mineral density and reduces back pain in β-thalassaemia patients with osteoporosis: results from a phase 2, randomized, parallel-arm, open-label study. Br J Haematol. 2012; 158: 274-82.
16. Riggs BL, Melton LJ. Medical progress series: involutional osteoporosis. N Engl J Med 1986. 314: 1676-86.
17. Kanis JA, Oden A, Johnell O, Johansson H, De Laet C, Brown J, et al. The use of clinical risk factors enhances the performance of BMD in the prediction of hip and osteoporotic fractures in men and women. Osteoporos Int. 2007; 18: 1033-46.
18. Kanis JA, Oden A, Johansson H, Borgström F, Ström O, McCloskey E. FRAX and its applications to clinical practice. Bone. 2009; 44: 734-43.
19. Adami S, Romagnoli E, Carnevale V, Scillitani A, Giusti A, Rossini M, et al. Guidelines on prevention and treatment of vitamin D deficiency. Reumatismo. 2011; 63: 129-47.
20. Giusti A, Papapoulos SE. Treatment of male osteoporosis with bisphosphonates. In: E. Orwoll, J. Bilezikian and D. Vanderschueren, eds. Osteoporosis in men. 2nd ed. New York, NY: Academic Press; 2009; Chapter 54: 667-79.
21. Kaufman JM, Audran M, Bianchi G, Braga V, Diaz-Curiel M, Francis RM, et al. Efficacy and safety of strontium ranelate in the treatment of osteoporosis in men. J Clin Endocrinol Metab. 2013; 98: 592-601.
22. Kaufman JM, Reginster JY, Boonen S, Brandi ML, Cooper C, Dere W, et al. Treatment of osteoporosis in men. Bone. 2013; 53: 134-44.
23. Orwoll ES, Scheele WH, Paul S, Adami S, Syversen U, Diez-Perez A, et al. The effect of teriparatide [human parathyroid hormone (1-34)] therapy on bone density in men with osteoporosis. J Bone Miner Res. 2003; 18: 9-17.
24. Boonen S, Reginster JY, Kaufman JM, Lippuner K, Zanchetta J, Langdahl B, et al. Fracture risk and zoledronic acid therapy in men with osteoporosis. N Engl J Med. 2012; 367: 171-423.
25. Orwoll E, Teglbjaerg CS, Langdahl BL, Chapurlat R, Czerwinski E, Kendler DL, et al. A randomized, placebo-controlled study of the effects of denosumab for the treatment of men with low bone mineral density. J Clin Endocrinol Metab. 2012; 97: 3161-9.
26. Saag KG, Shane E, Boonen S, Marìn F, Donley DW, Taylor KA, et al. Teriparatide or alendronate in glucocorticoid-induced osteoporosis. N Engl J Med. 2007; 357: 2028-39.
27. Smith MR, Egerdie B, Hernàndez Toriz N, Feldman R, Tammela TL, et al. Denosumab in men receiving androgen-deprivation therapy for prostate cancer. N Engl J Med. 2009; 361: 745-55.
28. Lyles KW, Colòn-Emeric CS, Magaziner JS, Adachi JD, Pieper CF, Mautalen C, et al. Zoledronic acid and clinical fractures and mortality after hip fracture. N Engl J Med. 2007; 357: 1799-809.